An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Athersys to Participate in The American Society for Neural Therapy and Repair Annual Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Athersys (NASDAQ: ATHX), a regenerative medicine company, will participate in The American Society for Neural Therapy and Repair Annual Conference from April 27-30, 2023, in Clearwater, FL. Dr. Sarah Busch, VP of Regenerative Medicine, will present a talk titled “MultiStem® Cellular Therapy for Neurological Indications” on April 28th at 9:00 a.m. ET and partake in a panel discussion on the career development of female neuroscientists later that day at 4:50 p.m. ET. Additionally, she will co-chair a panel on translating treatments for neural injury on April 29th at 2:30 p.m. ET. Athersys aims to advance knowledge in the field and explore collaborative opportunities at this prestigious event.
Positive
None.
Negative
None.
CLEVELAND--(BUSINESS WIRE)--
Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced today their participation in The American Society for Neural Therapy and Repair Annual Conference from April 27-30, 2023 in Clearwater, FL.
The American Society for Neural Therapy and Repair is a society of basic and clinical neuroscientists with a mission to better understand the way the nervous system functions and establish new procedures for its repair in response to trauma or neurodegenerative disease.
Dr. Sarah Busch, Vice President of Regenerative Medicine and Head of Business Development, has been invited to participate in this conference. On Friday, April 28th, she will be giving a talk in the morning titled “MultiStem® Cellular Therapy for Neurological Indications” during the Cell Therapies for Neural Repair session and will participate in a panel discussion later in the day titled, “Career Retention and Development of Female Neuroscientists.” On April 29th, Dr. Busch will be co-chairing the “Translating Treatments for Neural Injury & Disease” panel discussion.
“As a company with a broad pipeline focused on treatment of neurological indications, we are excited for the opportunity to share the progress we’ve made with MultiStem and engage with other experts in the field of neuroscience,” commented Dr. Busch. “We are enthusiastic about the potential for collaboration and knowledge exchange that this event offers as we continue to drive forward in our mission to extend and enhance the quality of human life."
The following are specific details regarding Dr. Busch's participation in The American Society for Neural Therapy and Repair Annual Conference:
Event:
Platform Presentation, “MultiStem® Cellular Therapy for Neurological Indications”
Date:
Friday, April 28th, 2023
Time:
9:00 a.m. ET
Location:
Sheraton Sand Key Resort, Clearwater Beach, Florida U.S.A.
Event:
Panel Discussion, “Career Retention and Development of Female Neuroscientists”
Date:
Friday, April 28th, 2023
Time:
4:50 p.m. ET
Location:
Sheraton Sand Key Resort, Clearwater Beach, Florida U.S.A.
Event:
Co-Chair for Panel Discussion, “Translating Treatments for Neural Injury & Disease”
Date:
Saturday, April 29th, 2023
Time:
2:30 p.m. ET
Location:
Sheraton Sand Key Resort, Clearwater Beach, Florida U.S.A.
Athersys is a biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived “off-the-shelf” stem cell product, initially for disease indications in the neurological, inflammatory and immune, and other critical care indications and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and a broad network of collaborations to further advance MultiStem cell therapy toward commercialization. Investors and others should note that we may post information about the Company on our website at www.athersys.com and/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms. It is possible that the postings could include information deemed to be material information. Therefore, we encourage investors, the media and others interested in the Company to review the information we post on our website at www.athersys.com and on our social media accounts. Follow Athersys on Twitter at www.twitter.com/athersys. Information that we may post about the Company on our website and/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. You should not place undue reliance on forward-looking statements contained on our website and/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms, and we undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.
About MultiStem®
MultiStem® (invimestrocel) cell therapy is a patented regenerative medicine product in clinical development that has shown the ability to promote tissue repair and healing in a variety of ways, such as through the production of therapeutic factors in response to signals of inflammation and tissue damage. MultiStem therapy’s potential for multidimensional therapeutic impact distinguishes it from traditional biopharmaceutical therapies focused on a single mechanism of benefit. The therapy represents a unique "off-the-shelf" stem cell product that can be manufactured in a scalable manner, may be stored for years in frozen form, and is administered without tissue matching or the need for immune suppression. Based upon its efficacy profile, its novel mechanisms of action, and a favorable and consistent tolerability demonstrated in clinical studies, we believe that MultiStem therapy could provide a meaningful benefit to patients, including those suffering from serious diseases and conditions with unmet medical need.
Athersys Ellen Gurley Manager of Corporate Communications and Investor Relations
ir@athersys.com
LHA Investor Relations
Tirth T. Patel 212-201-6614
tpatel@lhai.com
Source: Athersys, Inc.
FAQ
What is Athersys participating in during April 2023?
Athersys is participating in The American Society for Neural Therapy and Repair Annual Conference from April 27-30, 2023, in Clearwater, FL.
Who will represent Athersys at the conference?
Dr. Sarah Busch, Vice President of Regenerative Medicine, will represent Athersys at the conference.
When will Dr. Busch present her talk on MultiStem?
Dr. Busch will present her talk titled 'MultiStem® Cellular Therapy for Neurological Indications' on April 28th, 2023, at 9:00 a.m. ET.
What panel discussions will Dr. Busch participate in?
Dr. Busch will participate in two panel discussions: one on career retention for female neuroscientists on April 28th at 4:50 p.m. ET, and she will co-chair a panel on translating treatments for neural injury on April 29th at 2:30 p.m. ET.
Where is the American Society for Neural Therapy and Repair conference held?
The conference is held at the Sheraton Sand Key Resort in Clearwater Beach, Florida.
